Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ManiTSE:7730 -1.31%93 EBIT per Share is 円92.60 as of Feb. 2026. GuruFocus rates TSE:7730 with a GF Score™ of 93/100 and a GF Value™ of 円2,131.50 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 685 Medical Devices & Instruments companies, Mani ranks better than 50.8% on this metric.
Mani's EBIT per Share for the
three
months ended in Feb. 2026 was 円29.80.
Its EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 was 円92.60.
During the past 12 months, the average EBIT per Share Growth Rate of Mani was 9.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 9.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 14.30% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 7.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Mani's EBIT per Share or its related term are showing as below:
TSE:7730'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -19.9 Med: 5.4 Max: 32.6
Current: 9.9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Mani was 32.60% per year. The lowest was -19.90% per year. And the median was 5.40% per year.
TSE:7730's 3-Year EBIT Growth Rate is ranked better than 50.8% of 685
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs TSE:7730: 9.90
Mani's EBIT for the
three
months ended in Feb. 2026 was 円2,935 Mil.
Mani (TSE:7730) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Mani EBIT per Share Related Terms
Mani EBIT per Share Historical Data
* Premium members only.
The historical data trend for Mani's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円92.60
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mani (TSE:7730) has a EBIT per Share of 円92.60 as of Feb. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Mani and its competitors. According to the industry distribution chart, Mani ranks #337 out of 685 companies in the Medical Devices & Instruments industry, placing it in the top 49.2%.
Is Mani's EBIT per Share too high?
Mani's current EBIT per Share is 円92.60. Based on the distribution chart, Mani ranks #337 out of 685 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Mani has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mani's EBIT per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Mani ranks #337 out of 685 companies for EBIT per Share. This puts Mani in the upper half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Mani and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mani's current EBIT per Share is 円92.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mani stock overvalued right now?
Based on GuruFocus' analysis, Mani (TSE:7730) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,131.50, compared to a current price of 円1,580.00 — trading 25.9% below its estimated fair value. The current EBIT per Share is 円92.60. Mani's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Mani (TSE:7730), the current EBIT per Share is 円92.60 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mani (TSE:7730) Overvalued in 2026?
Based on GuruFocus' analysis, Mani stock appears to be undervalued.
The current stock price of 円1,580.00 is trading 25.9% below its estimated GF Value™ of 円2,131.50.
GuruFocus considers Mani to be Modestly Undervalued.
Key valuation signals for TSE:7730:
EBIT per Share: 円92.60
GF Value™: 円2,131.50 vs. price of 円1,580.00 (25.9% below fair value)
No single metric tells the full story. See the TSE:7730 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mani Inc manufactures medical devices and dental instruments. It sells products in four categories: surgical instruments, ophthalmic instruments, suture needles, and dental instruments. Mani's surgical products include instruments such as staplers, vessel knives, and bone saws. Its ophthalmic instruments include a range of knives used during eye surgery and ophthalmic sutures. Mani's suture needles business includes a variety of taper point and cutting eyeless needles, which require suture attachment and sterilization by the customer, as well as stainless-steel eyed needles. The firm's dental instruments include endodontic instruments and accessories, root canal equipment, and finishing and polishing instruments.
93GF Score
Get the complete analysis for TSE:7730
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7730 has been successfully added to your 
